ABSTRACT
The Spanish Quality Assurance Program applied to the process of donation after brain death entails an internal stage consisting of a continuous clinical chart review of deaths in critical care units (CCUs) performed by transplant coordinators and periodical external audits to selected centers. This paper describes the methodology and provides the most relevant results of this program, with information analyzed from 206,345 CCU deaths. According to the internal audit, 2.3% of hospital deaths and 12.4% of CCU deaths in Spain yield potential donors (clinical criteria consistent with brain death). Out of the potential donors, 54.6% become actual donors, 26% are lost due to medical unsuitability, 13.3% due to refusals to donation, 3.1% due to maintenance problems and 3% due to other reasons. Although the national pool of potential donors after brain death has progressively decreased from 65.2 per million population (pmp) in 2001 to 49 pmp in 2010, the number of actual donors after brain death has remained at about 30 pmp. External audits reveal that the number of actual donors could be 21.6% higher if all potential donors were identified and preventable losses avoided. We encourage other countries to develop similar comprehensive approaches to deceased donation performance.
Subject(s)
Quality Assurance, Health Care , Tissue and Organ Procurement , Humans , SpainABSTRACT
The fight against chronic kidney disease is one of the most relevant aspects of nephrological practice, from both the perspective of clinical activity and research within the field of nephrology. In this brief article, we present in very summarized form some of the aspects in this field in the last year that the authors found of interest. Because the content of the next few pages was necessarily chosen on the basis of the authors' preferences, we assume that many other topics of great interest have been left out of this summary. In any case, we hope that this article will be interesting and useful and also serve as an subject of debate in nephrology forums.
Subject(s)
Kidney Diseases/physiopathology , Adult , Amidohydrolases/genetics , Amidohydrolases/physiology , Animals , Arginine/analogs & derivatives , Arginine/blood , Carbon/therapeutic use , Cardiovascular Diseases/epidemiology , Cardiovascular Diseases/etiology , Chronic Disease , Clinical Trials as Topic , Disease Progression , Female , Genetic Therapy , Humans , Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use , Infant, Low Birth Weight , Infant, Newborn , Kidney Diseases/drug therapy , Kidney Diseases/embryology , Kidney Diseases/metabolism , Male , Oxides/therapeutic use , Pregnancy , Prenatal Exposure Delayed Effects , Rats , Uremia/metabolism , Uric Acid/bloodABSTRACT
Essential hypertension patients can be divided into two groups on the basis of the presence or absence of a plasma factor able to inhibit rubidium uptake and sodium extrusion by the red blood cells. Nearly fifty percent of the patients studied present this factor. Preliminary results show that it is dialyzable, has a molecular weight around 500 daltons and cannot be extracted by chloroform.
